Market Overview:
The global preclinical CRO treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing demand for contract research services from biopharmaceutical companies, government and academic institutes, and medical device companies. Additionally, the growing focus on personalized medicine is also contributing to the growth of this market. The bioanalysis and DMPK studies segment is expected to account for the largest share of the global preclinical CRO treatment market in 2018. This segment is expected to grow at a CAGR of 7.8% from 2018 to 2030 due to the increasing demand for contract research services for drug discovery and development activities.
Product Definition:
Preclinical CRO Treatment is the term used to describe the drug development process that occurs before a product can be submitted for approval by regulatory agencies such as the Food and Drug Administration (FDA) in the United States or European Medicines Agency (EMA) in Europe. The preclinical stage of drug development typically involves activities like safety testing, efficacy testing, and manufacturing studies.
Bioanalysis and DMPK Studies:
Bioanalysis and DMPK studies are the core of Preclinical CRO treatment. It is used for measuring the concentration of a therapeutic compound in biological fluids such as serum, plasma or urine. The bioanalysis and DMPK study is an important step in drug development because it helps to identify toxic effects & efficacy profile of new drug before conducting clinical trials on human beings.
Toxicology Testing:
The toxicology testing is a procedure carried out to evaluate the toxicity of an upcoming drug or chemical. It's primary function is to identify the harmful effects that may occur in humans after taking a particular drug. The tests are usually carried out on animals (mice, rats, and dogs) before human trials start.
Application Insights:
The biopharmaceutical companies segment dominated the global preclinical CRO treatment market in 2017. This can be attributed to factors such as increasing government funding for drug development and growing emphasis on reducing costs. Moreover, an increase in the number of new drugs approved by FDA during recent years has also positively influenced segment growth. For instance, Pfizer Inc., a U.S.-based multinational pharmaceutical company; recently received FDA approval for its new drug ZINPLAVA (bezlotoxumab) injection for plaque psoriasis (moderate-to-severe) through an accelerated approval process (Pfizer 2016).
Preclinical pharmacokinetic and pharmacodynamic profiling is carried out to identify suitable dosage forms and delivery systems of medicines that are intended for clinical trials so as to reduce the risk of adverse effects while maintaining efficacy throughout the course of therapy (Biosite 2014).
Regional Analysis:
North America dominated the global preclinical CRO treatment market in 2017. This can be attributed to the presence of a large number of biopharmaceutical and academic research organizations, which are engaged in drug discovery and development processes. The U.S.-based companies have significantly contributed to the growth of this regional market through their consistent efforts for drug discovery and development processes, along with an increase in R&D spending by them over the past few years.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to increasing government funding for biomedical research coupled with rising healthcare expenditure levels by various governments across this region as well as other regions around the world (e.g., North America). These aforementioned factors are anticipated to boost demand for preclinical CRO services within Asia Pacific over next eight years, thereby driving growth within this region during forecast period from 2018 to 2030 (see Table 1).
Growth Factors:
- Increasing demand for novel therapeutics and personalized medicines
- Rising prevalence of chronic diseases
- Growing number of clinical trials and drug approvals
- Advances in CRO services and technologies
- Expansion of the Preclinical CRO Treatment market into emerging economies
Scope Of The Report
Report Attributes
Report Details
Report Title
Preclinical CRO Treatment Market Research Report
By Type
Bioanalysis and DMPK Studies, Toxicology Testing, Others
By Application
Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies
By Companies
Charles River Laboratories, Laboratory Corporation of America, Envigo, Eurofins Scientific, PRA Health Science, Wuxi AppTec, Medpace, Pharmaceutical Product Development, Paraxel
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Preclinical CRO Treatment Market Report Segments:
The global Preclinical CRO Treatment market is segmented on the basis of:
Types
Bioanalysis and DMPK Studies, Toxicology Testing, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Charles River Laboratories
- Laboratory Corporation of America
- Envigo
- Eurofins Scientific
- PRA Health Science
- Wuxi AppTec
- Medpace
- Pharmaceutical Product Development
- Paraxel
Highlights of The Preclinical CRO Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Bioanalysis and DMPK Studies
- Toxicology Testing
- Others
- By Application:
- Biopharmaceutical Companies
- Government and Academic Institutes
- Medical Device Companies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Preclinical CRO Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Preclinical CRO treatment is a process of identifying and testing potential drugs or therapies that could be used to treat diseases in animals before they are ever tested on humans. This can help researchers learn more about the potential benefits and risks of these treatments before they are put into larger, more rigorous clinical trials.
Some of the major companies in the preclinical cro treatment market are Charles River Laboratories, Laboratory Corporation of America, Envigo, Eurofins Scientific, PRA Health Science, Wuxi AppTec, Medpace, Pharmaceutical Product Development, Paraxel.
The preclinical cro treatment market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Preclinical CRO Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Preclinical CRO Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Preclinical CRO Treatment Market - Supply Chain
4.5. Global Preclinical CRO Treatment Market Forecast
4.5.1. Preclinical CRO Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Preclinical CRO Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Preclinical CRO Treatment Market Absolute $ Opportunity
5. Global Preclinical CRO Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Preclinical CRO Treatment Market Size and Volume Forecast by Type
5.3.1. Bioanalysis and DMPK Studies
5.3.2. Toxicology Testing
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Preclinical CRO Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Preclinical CRO Treatment Market Size and Volume Forecast by Application
6.3.1. Biopharmaceutical Companies
6.3.2. Government and Academic Institutes
6.3.3. Medical Device Companies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Preclinical CRO Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Preclinical CRO Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Preclinical CRO Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Preclinical CRO Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Preclinical CRO Treatment Demand Share Forecast, 2019-2029
9. North America Preclinical CRO Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Preclinical CRO Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Preclinical CRO Treatment Market Size and Volume Forecast by Application
9.4.1. Biopharmaceutical Companies
9.4.2. Government and Academic Institutes
9.4.3. Medical Device Companies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Preclinical CRO Treatment Market Size and Volume Forecast by Type
9.7.1. Bioanalysis and DMPK Studies
9.7.2. Toxicology Testing
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Preclinical CRO Treatment Demand Share Forecast, 2019-2029
10. Latin America Preclinical CRO Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Preclinical CRO Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Preclinical CRO Treatment Market Size and Volume Forecast by Application
10.4.1. Biopharmaceutical Companies
10.4.2. Government and Academic Institutes
10.4.3. Medical Device Companies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Preclinical CRO Treatment Market Size and Volume Forecast by Type
10.7.1. Bioanalysis and DMPK Studies
10.7.2. Toxicology Testing
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Preclinical CRO Treatment Demand Share Forecast, 2019-2029
11. Europe Preclinical CRO Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Preclinical CRO Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Preclinical CRO Treatment Market Size and Volume Forecast by Application
11.4.1. Biopharmaceutical Companies
11.4.2. Government and Academic Institutes
11.4.3. Medical Device Companies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Preclinical CRO Treatment Market Size and Volume Forecast by Type
11.7.1. Bioanalysis and DMPK Studies
11.7.2. Toxicology Testing
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Preclinical CRO Treatment Demand Share, 2019-2029
12. Asia Pacific Preclinical CRO Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Preclinical CRO Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Preclinical CRO Treatment Market Size and Volume Forecast by Application
12.4.1. Biopharmaceutical Companies
12.4.2. Government and Academic Institutes
12.4.3. Medical Device Companies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Preclinical CRO Treatment Market Size and Volume Forecast by Type
12.7.1. Bioanalysis and DMPK Studies
12.7.2. Toxicology Testing
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Preclinical CRO Treatment Demand Share, 2019-2029
13. Middle East & Africa Preclinical CRO Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Preclinical CRO Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Preclinical CRO Treatment Market Size and Volume Forecast by Application
13.4.1. Biopharmaceutical Companies
13.4.2. Government and Academic Institutes
13.4.3. Medical Device Companies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Preclinical CRO Treatment Market Size and Volume Forecast by Type
13.7.1. Bioanalysis and DMPK Studies
13.7.2. Toxicology Testing
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Preclinical CRO Treatment Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Preclinical CRO Treatment Market: Market Share Analysis
14.2. Preclinical CRO Treatment Distributors and Customers
14.3. Preclinical CRO Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Charles River Laboratories
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Laboratory Corporation of America
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Envigo
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Eurofins Scientific
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. PRA Health Science
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Wuxi AppTec
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Medpace
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Pharmaceutical Product Development
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Paraxel
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook